NCT00424866View on ClinicalTrials.gov

FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

June 30, 2022

Conditions
Peripheral Arterial DiseaseStenosisIntermittent Claudication
Interventions
DRUG

FGF-1

"Doses of FGF-1: 3 ug/kg; 10 ug/kg; 30 ug/kg~Low dose: 3.0 μg/kg Mid dose: 10 μg/kg High dose: 30 µg/kg"

DRUG

Placebo

Vehicle: 0 µg/kg

Trial Locations (1)

75238

CVBT Info, Dallas

Sponsors
All Listed Sponsors
lead

CardioVascular BioTherapeutics, Inc.

INDUSTRY